CRISPR therapeutics push into human testing

The first clinical trial in the US of a therapy based on the CRISPR–Cas9 gene editing

system is more likely to be conducted by an academic group than by one of the biotech

firms most closely associated with the commercial development of the technology.

Nat Biotechnol. 2017 Jan 10;35(1):3-5.

Para acessar a publicação na íntegra clique aqui